healthcare
Q&A: Hony Capital's John Zhao
Hony Capital CEO John Zhao expects to see more control opportunities arising from domestic succession planning, cross-border expansion and restructuring. He explains how his firm is preparing the ground
China hospitals: Complicated prescription
Private equity investors see huge opportunities in China’s hospital space on the back of healthcare reforms. But valuations are high, doctors are in limited supply, and regulation can be a headache
China’s BeiGene raises $97m from PE investors
BeiGene, a Chinese company that develops drugs to combat cancer, has raised RMB600 million ($97 million) in a funding round led by existing investors Hillhouse Capital and an undisclosed US-based life sciences-focused public investment fund.
Taiwan's JHL Biotech raises $45m in Series C round
Taiwan-based biopharmaceutical company JHL Biotech has raised a $45 million Series C round, led by an unnamed investor. Existing backer Milestone Capital also participated, along with newcomers Sungent BioVenture and Liwick Investment Management.
CLSA seals second Asia diapers deal
CLSA Capital Partners (CLSA CP) has invested RMB150 million ($24.5 million) in Coco Healthcare Products, a Chinese manufacturer of diapers for adults and babies. It plans to help the company boost its export business.
Korea’s Posco, Green Cross lead round for US-based Juventas
South Korea-based Posco Capital and biopharmaceutical player Green Cross have led a $7.5 million round for Juventas Therapeutics, a clinical-stage biotech development company based in the US.
Deal focus: A Sino-French solution to liver disease
Inner Mongolia FuRui Medical Science (FuRui) started out two decades ago as a pure-play drug manufacturer, but then it found its niche developing diagnostic equipment and treatment for liver disease. Looking to bring in overseas technology, it acquired...
Ally Bridge supports WuXi PharmaTech take-private
WuXi PharmaTech, a China-based provider of contract R&D services to the global pharmaceutical sector, has received a take-private bid led by its founder and chairman and healthcare-focused PE firm Ally Bridge Group.
India's Fortis to sell Singapore unit for $83.5m
India's Fortis Healthcare will sell its Singapore-based diagnostics arm RadLink-Asia to Fullerton Healthcare Group for S$111 million ($83.5 million).
Cathay Capital leads round for FuRui’s medical device unit
Cathay Capital has led a EUR30 million ($33 million) round of funding for Echosens, a France-based diagnostic medical device manufacturer owned by China’s Inner Mongolia FuRui Medical Science.
China’s Huakang Mobile Healthcare raises $32m from VCs
Yunfeng Capital, Shenzhen Cowin Capital, New Horizon Capital and Hunan Haijie Healthcare Investment have provided RMB200 million ($32 million) in Series B funding for Huakang Mobile Healthcare, a Chinese mobile healthcare app developer.
KKR-backed China Cord Blood gets buyout offer from Golden Meditech
China Cord Blood, a US-listed blood banking operator in which KKR holds a minority stake, has received a take-private offer from its largest shareholder, Chinese healthcare company Golden Meditech.
Fund focus: Brandon secures super fund support
With A$78 billion ($61 billion) in assets, AustralianSuper is said to struggle to make fund commitments of less than A$150 million. Yet it is one of several superannuation funds backing Brandon Capital’s latest life sciences VC vehicle, which has closed...
Fosun, Tencent lead $35m round for US medical device start-up
China's Fosun International and Tencent Holdings have led a $35 million Series B round for Scanadu, a US-based medical technology start-up working on devices that can send diagnostic tests directly to smart phones.
Singapore doctor discovery platform DocDoc raises $8.5m
DocDoc, the Singapore-based start-up behind the Asian doctor discovery platform of the same name, has raised a Series A round worth S$11.5 million ($8.5 million) from US and Korea-based SparkLabs Global Ventures, and Malaysian conglomerate Hong Leong...
Biocon to list IVFA-backed India CRO unit
Indian biopharmaceutical firm Biocon has filed for an IPO for its research arm Syngene International, which is backed by India Value Fund Advisors (IVFA).
EQT-backed LBX hits trading cap on Shanghai debut
Laobaixing Pharmacy Chain (LBX Pharmacy), a Chinese retail pharmacy chain backed by EQT Partners, closed up 44% on its price on the first day of trading in Shanghai.
PE investors to participate in $645m China TCM placement
GIC Private, China Renaissance Capital Investment (CRCI) and GL Capital Group are among 26 investors subscribing to a HK$5 billion ($645 million) share placement by China Traditional Chinese Medicine (China TCM), intended to generate capital for acquisitions.
Brandon raises $154m for Australia life sciences fund
Australian life sciences-focused VC firm Brandon Capital has reached a A$200 million ($154 million) final close on its latest vehicle - the Medical Research Commercialisation Fund 3 (MRCF 3).
Temasek invests $151m in India's Glenmark Pharma
Singapore state-backed investment group Temasek Holdings has invested INR9.45 billion ($151 million) in India's Glenmark Pharma via a preferential allotment of shares.
Hony in $1.26b CSPC Pharma share sale
Hony Capital has sold HK$9.78 billion ($1.26 billion) worth of shares in CSPC Pharmaceutical to complete its exit from the Hong Kong-listed Chinese drug manufacturer.
Alibaba injects online pharmacy business into HK-listed unit
Alibaba Group plans to inject the operations of its online pharmacy business into Alibaba Health Information Technology (Alibaba Health), a Hong Kong-listed healthcare company that it bought alongside Yungfeng Capital last year, in a deal worth HK$19.4...
TVM reaches $50m first close on China pharma fund
TVM Capital Life Science has reached a first close of $50 million on its debut China fund, which will invest in Western companies with a view to obtaining licenses for development and commercialization in China.
Warburg Pincus exits India healthcare chain Metropolis
Warburg Pincus has exited its entire 27% stake in Indian healthcare chain Metropolis to the Shah family, one of the company's promoters. KKR backed the Shah family's buyback.